Product methodology
Anesthesia Outcomes Shadow Registry
Source contract, normalization path, entity-graph join, refresh posture, and publication limits for this Branmoor product.
Status
In service. This product has a functional preview or paid engagement surface in the current site. The full licensed product may still include private exports, alerts, APIs, or buyer-specific diligence that are not exposed publicly.
Distribution Scope
Nationwide; TN ASC layer; Nashville ASC/anesthesia watch
Product Question
Aggregates anesthesia outcome and malpractice/procedure-risk signals.
Primary Sources
- CMS Medicare and Medicaid claims — Anesthesia procedure volume, complications, comorbidity
- NPDB malpractice query data (provider self-query where disclosed) — Claims and licensure actions
- State malpractice disclosure (where public) — Provider-level claims history
- Hospital quality reports and accreditation databases — Facility safety and surgical outcome data
- FDA MAUDE — Anesthesia equipment-related adverse events
Entity-Graph Join
ASC/hospital `ccn`, clinician `npi`, device IDs, procedure codes.
Publication Rule
Branmoor does not treat raw public records as the product. A surface is publishable only when the source record is dated, normalized, source-linked, and joined to the relevant Branmoor entity identifiers with enough confidence to state the limits of the result.
Current Methodology Note
v1 surfaces every Medicare-certified Ambulatory Surgical Center with the CMS-published anesthesia-adjacent quality measures: patient burns, falls, wrong-site events, normothermia outcomes, and risk-standardized post-procedure hospital-visit rates. The paid Shadow Registry layer attributes the anesthesia-specific component using NPDB cross-reference, state malpractice disclosure (where public), CMS Medicare claims, and FDA MAUDE for anesthesia equipment.
Limits
Coverage follows the underlying source. Missing state portals, gated APIs, PDF-only filings, suppressed fields, lagged agency refreshes, and entity-name ambiguity can all limit product completeness. Pending products are not marketed as live until those limits are documented on the product surface.